NEW YORK (GenomeWeb News) – Rosetta Genomics announced today that its Rosetta Cancer Origin Test has received in-network provider status with Highmark Health Services.
Highmark Health is a subsidiary of Highmark and the fourth-largest Blue Cross Blue Shield-affiliated company, providing coverage for 5.3 million people in Pennsylvania, Delaware, and West Virginia. Its members now have access to Rosetta's test for identifying the tumor origin in cancer of unknown or uncertain primary as an in-network service.
"Over the past six months we have made considerable progress executing credentialing agreements with large, national preferred provider organizations, thereby expanding the coverage for the Rosetta Cancer Origin Test to one in five Americans," Rosetta President and CEO Kenneth Berlin said in a statement. "This is increasingly important as enhanced awareness of our test and the accurate identification of tumor origin in patients with metastatic cancer has resulted in record volumes of samples processed and billed at our CLIA lab over the past three months."
In September Rosetta announced deals covering the Cancer Origin Test with FedMed and Fortified Provider Network.